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ABSTRACT
In recent years, tremendous insight has been gained
on p53 regulation by targeting mutations at the
p53 locus using homologous recombination in ES
cells to generate mutant mice. Although informative,
this approach is inefficient, slow and expensive.
To facilitate targeting at the p53 locus, we devel-
oped an improved Recombinase-Mediated Cassette
Exchange (RMCE) method. Our approach enables
efficient targeting in ES cells to facilitate the pro-
duction of mutant mice. But more importantly, the
approach was Adapted for targeting in Somatic cells
to Accelerate Phenotyping (RMCE-ASAP). We pro-
vide proof-of-concept for this at the p53 locus, by
showing efficient targeting in fibroblasts, and rapid
phenotypic read-out of a recessive mutation after a
single exchange. RMCE-ASAP combines inverted
heterologous recombinase target sites, a positive/
negative selection marker that preserves the germ-
line capacity of ES cells, and the power of mouse
genetics. These general principles should make
RMCE-ASAP applicable to any locus.
INTRODUCTION
p53 is one of the most highly analyzed proteins for the past
25 years. Studies in cultured cells, often relying on the trans-
fection of plasmids expressing various p53 mutants, have
established models to explain how p53 is regulated. In recent
years, some of these models were tested in vivo by targeting
subtle mutations at the p53 locus using homologous recombi-
nation in embryonic stem (ES) cells to generate mutant
mice. The strength of this approach is that mutations are
tested in a genomic setting and expressed from the endoge-
nous promoter, ensuring physiological expression levels and
correct spatio-temporal proﬁles. As signiﬁcant differences
between phenotypes from targeted p53 mutants in vivo and
transfection data were observed [e.g. Refs (1–5)], more
targeted mutations need to be generated and analyzed in
multiple tissues to formulate more accurate models of p53
regulation.
However, using homologous recombination in ES cells to
generate mutant mice is an inefﬁcient, slow and expensive
method because (i) homologous recombination typically
occurs at low frequency in ES cells, requiring sophisticated
selection schemes and screening of hundreds of clones to
identify the desired mutant; (ii) large (15–20 kb) plasmids,
often difﬁcult to clone, are required to increase targeting efﬁ-
ciency and (iii) breeding mice to homozygosity and housing
a mouse colony generate further delays and costs. Such limi-
tations make the repeated targeting of a locus a technically
daunting and economically impractical task.
Improvements in current technologies are needed to enable
such analyses to be applied to the p53 or other genes. Devel-
oping methods to increase targeting efﬁciency in ES cells is
clearly an important goal. In addition, efﬁcient methods for
gene targeting in ﬁbroblasts could expedite phenotypic anal-
yses. Indeed, siRNAs in ﬁbroblasts often provide a faster read-
out than equivalent gene knock-outs in animals (6). However,
modeling most disease-associated mutations requires generat-
ing subtle mutations, not knock-outs or reduced expression
alleles. Targeting point mutations in ﬁbroblasts by homologous
recombination is extremely inefﬁcient, and targeting both alle-
les is required to reveal the phenotype of recessive autosomal
mutations.
Here we report an approach that enables highly efﬁ-
cient targeting at the p53 locus in both ES cells and ﬁbrob-
lasts. Recombinase-Mediated Cassette Exchange (RMCE)
approaches were developed to improve targeting efﬁciency
using a two-step process: the gene of interest is ﬁrst replaced
by a selection cassette ﬂanked by recombinase target sites
(e.g. loxP sites for Cre recombinase, to create a ‘ﬂoxed’
locus). Then, Cre-mediated recombination in the presence
of a cassette containing a ﬂoxed mutant allele removes the
resident sequence and inserts the mutant gene (7). Previously,
technical difﬁculties have prevented RMCE from being
applied routinely to generate mutant mice. For example,
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were inefﬁcient because excisions dominated the intended
exchanges (8). loxP sites with different sequences were gen-
erated to overcome this problem, but these sites also under-
went intramolecular recombination, making RMCE efﬁcient
only if the replacement cassette contained a marker enabling
selection of the desired recombinant (7,9–12). However,
interference resulting from expression of the selection
marker and the endogenous gene (13) necessitates strategies
to remove the selectable gene. Together, previous studies
indicate that an optimal RMCE requires (i) inverted heterolo-
gous loxP sites diverging by at least 2 nt to maximize the efﬁ-
ciency of exchange and (ii) an expression cassette enabling
both positive selection to identify the initial recombinant
and then negative selection to obtain a ‘marker-free’ mutant
allele (14).
Most RMCE experiments have been performed at random
sites in somatic cell lines. Only a few mutant mice generated
by RMCE in ES cells have been reported, but the RMCE
systematically introduced a selectable marker (15–17), or,
when tested without an incoming marker, proved inefﬁcient
(12). A recent report disclosed an additional problem: the
Hygromycin–Thymidine Kinase fusion gene used most fre-
quently for positive/negative selection in RMCE, leads to
mouse sterility, so that exchanges can only be performed in
ES cells (16).
The RMCE strategy presented here relies on the integrated
use of inverted heterologous loxP sites, a positive/negative
selection marker that preserves the germline capacity of ES
cells, and the power of mouse genetics to expedite phenotypic
analyses. We show that our approach enables efﬁcient target-
ing of marker-free mutations at the p53 locus in ES cells
to generate mutant mice, but more importantly, it is Adapted
for targeting in Somatic cells to Accelerate Phenotyp-
ing (ASAP). Because it relies on very general principles,
RMCE-ASAP could be applied to any locus of interest.
MATERIALS AND METHODS
Targeting construct for a p53 RMCE-ready locus
Details for plasmid construction are available upon request
owing to space limitations mandating a brief outline. We
started from a plasmid L3-1L containing heterologous loxP
sites (L3 is the mutant loxP257 recently described (14),
1L is an inverted WT loxP). The WT loxP and loxP257 differ
in their spacer sequences: the spacer sequence is 50-
ATGTATGC-30 for WT loxP and 50-AAGTCTCC-30 for
loxP257. The three mutations in the loxP257 spacer sequence
prevent it to recombine with WT loxP, ensuring efﬁcient
RMCE in several cell lines: accurate RMCE with these
loxP sites occurred with an average frequency of 81% at
two loci in CHO cells and an average frequency of 69% at
four loci in Hela cells (14). The L3-1L plasmid was ﬁrst
modiﬁed to include a ClaI and a FseI site between the
LoxP sites, leading to plasmid L3-CF-1L. We next modiﬁed
a puroDTK plasmid (YTC37, a kind gift from A. Bradley) by
using oligonucleotides to destroy a NotI site downstream of
the puroDTK gene and introduce a NotI site upstream, and
a FseI site downstream of the gene (leading to plasmid CN-
PuroDTK-F). Next, a PmlI-MfeI 6.3 kb fragment from Trp53
was subcloned in a modiﬁed pBluescript KSII+ (pBS, Strata-
gene), and the resulting plasmid was digested with SwaI to
introduce an EagI site, leading to p53PmlEag, a plasmid
containing exons 2–11 of p53. We then inserted a 5.5 kb
ClaI-EagI fragment from p53PmlEag in plasmid CN-
PuroDTK-F digested by ClaI and NotI, and inserted the
resulting fragment between the loxP sites of L3-CF-1L by
ClaI and FseI digestion, leading to L3-p53PmlEagPuroDTK-
-1L. We next engineered a plasmid containing the region for
30-homology downstream of the p53 gene and the DTA gene
in two steps: (i) we performed a three-way ligation between a
modiﬁed pBS digested by HindIII and NotI, a HindIII-EcoRI
fragment from Trp53 for 30homology and an EcoRI-NotI
fragment containing the DTA gene, from plasmid pgkdtabpa
(kind gift of P. Soriano), leading to plasmid 30 + DTA and
(ii) because the Bsu36I-EcoRI region downstream of p53 con-
tains repetitive sequences (F. Toledo and G. M. Wahl, unpub-
lished data), we later deleted this region, to obtain plasmid 30
+ DTA. The 50 homology consists of a 3.4 kb-long BamHI-
PmlI fragment from intron 1 of p53 cloned in a modiﬁed
pBS (plasmid p50). Finally, appropriate fragments from plas-
mids p50, L3-p53PmlEagPuroDTK-1L, and 30 + DTA were
assembled in a modiﬁed pSP72 plasmid (Promega). Plasmid
Flox, the resulting targeting construct, was veriﬁed by res-
triction analysis, then sequenced using 30 primers chosen to
precisely verify all p53 coding sequences, all exon–intron
junctions and the sequences at and around the loxP sites.




To make a p53-GFP fusion protein, we ﬁrst subcloned a
SacII-HindIII fragment of the p53 locus (corresponding to
part of exon 10 to sequences downstream of the gene) into
pBS, then mutated the HindIII site into a FseI site. We next
mutated the C-terminal part of the p53 gene in two rounds of
PCR mutagenesis, ﬁrst with primers 50-GGGCCTGACTCA-
GACGGATCCCCTCTGCATCCCGTC-30 and 50-GACGGG-
ATGCAGAGGGGATCCGTCTGAGTCAGGCCC-30, which
removed the stop codon and introduced a BamHI site, then
with primers 50-GACGGATCCCCTCTGAATTCCGTCCC-
CATCACCA-30 and 50-TGGTGATGGGGACGGAATACA-
GAGGGGATCCGTC-30, which introduced an EcoRI site.
We veriﬁed the sequence from the mutated plasmid, then
digested it with BamHI and EcoRI, to insert in frame GFP
sequences from a Bam HI-EcoRI fragment of plasmid
phr-GFP-1 (Stratagene). We veriﬁed the sequence of this
p53-GFP fusion fragment, then swapped it in the L3-
p53PmlEagPuroDTK-1L plasmid (see above) by HindIII and
FseI digestion, resulting in the p53
GFP exchange construct,
the sequence which was veriﬁed before use. The p53
DPGFP
exchange construct was engineered by combining sequences
from the p53
GFP exchange plasmid and sequences from the
p53
DP targeting construct described recently (5). Its sequence
was also veriﬁed before use.
Sequences and use of PCR primers
a: 50-CCCCGGCCCTCACCCTCATCTTCG-30, from the
PuDTK gene, assays targeting of Flox plasmid; b: 50-AACA-
AAACAAAACAGCAGCAACAA-30, from sequences down-
stream of the p53 gene and outside Flox sequences, assays








AA-30, from p53 intron 3, and e: 50-TCTAGACAGAGAAA-
AAAGAGGCATT-30, from p53 intron 4, assay RMCE with
p53
DPGFP plasmid; f: 50-ATGGGAGGCTGCCAGTCCTAA-
CCC and g: 50-GTGTTTCATTAGTTCCCCACCTTGAC-30
amplify the WT p53 allele according to Taconic’s proce-
dures, h: 50-TTTACGGAGCCCTGGCGCTCGATGT-30 and
i: 50-GTGGGAGGGACAAAAGTTCGAGGCC-30 amplify
the Neo marker in the p53 KO allele according to Taconic’s
procedures.
Cell culture conditions
Primary MEFs, isolated from 13.5 day embryos, were
cultured in DMEM with 15% FBS, 100 mM BME, 2 mM
L-glutamine and antibiotics. 129/SvJae ES cells were grown
in the same medium supplemented with 1000 U/ml
ESGRO (Chemicon), on a layer of mitomycin C-treated
SNLPuro-7/4 feeders (kind gift of A. Bradley). Selections
were performed with 2 mg/ml puromycin, 0.2 mM FIAU or
2 mM ganciclovir.
Targeting/genotyping of the RMCE-ready locus
29/SvJae ES cells were electroporated with the Flox construct
linearized with PmeI, and puromycin resistant clones were
analyzed as described (Figure 2). Two clones were injected
into blastocysts and transmitted through the germline.
Performing RMCE in ES cells
A total of 8 · 10
5 p53
RMCE/+ ES cells were grown without
puromycin for 12 h, electroporated with 15 mg CMV-Cre
plasmid (pOG231) and 200 mg of the exchange construct,
and plated in T25 ﬂasks at 10
5 cells per ﬂask. FIAU
was added to the medium 3–4 days after electroporation.
Figure 1. Rationale for a RMCE-ASAP. Using homologous recombination, the gene of interest (GOI, open boxes: exons), is targeted with a construct introducing
upstream of coding regions one loxP (blue arrowhead) and downstream, a positive/negative selection cassette (red box) and a second inverted heterologous loxP
(purple arrowhead) to create RMCE-ready ES cells. An exchange is performed in these cells by co-transfecting a Cre expression plasmid and a marker-free
plasmid with a floxed mutant GOI (green box: mutated exon), to produce a mutant mouse (path A). Importantly RMCE-ASAP incorporates two major
improvements over classical RMCE (path B): (i) the positive/negative selection cassette does not prevent germline transmission, so that RMCE-ready mice can
be obtained; (ii) the selection cassette does not replace, but rather lies downstream of the GOI. This is a crucial requirement for accelerated phenotyping in
somatic cells, as maintaining a functional GOI ensures that the RMCE-ready locus still behaves like a WT locus. Hence, after breeding the RMCE-ready mouse
with mice heterozygotes for the GOI, somatic cells with an RMCE-ready locus and a WT or KO allele can be recovered [e.g. RMCE/+ and RMCE/  mouse
embryonic fibroblasts (MEFs)]. Such cells, phenotypically similar to +/+ and +/  cells, can then be used for phenotypic analyses of dominant or recessive
mutations after a single exchange.
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grown in 96-well plates and expanded to generate duplicate
plates for freezing and DNA analysis by PCR and Southern.
Performing RMCE in MEFs
A total of 10
6 p53
RMCE/  MEFs cells were grown without
puromycin for 12 h, electroporated with 3 mg pOG231 and
30 mg exchange construct, and plated in a single 10 cm-dish,
grown for 3 days then split in several dishes at 10
5 cells per
dish. FIAU or ganciclovir was added to the medium 4 days
after electroporation, for 3–4 days. Clones, picked 10 days
after electroporation, were grown in 24-well plates and
expanded for freezing and DNA analysis.
Western-blots
Cells, untreated or treated for 24 h with 0.5 mg/ml adri-
amycin, were lysed on the dish in a buffer consisting of
50 mM Tris (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.5%
Nonidet P-40, 1 mM PMSF, 1 mM sodium vanadate,
10 mM NaF and Complete Mini Protease Inhibitors (Roche
Diagnostics) at 4 C for 30 min. Lysates were scraped, then
spun at 6000· g at 4 C for 10 min. Protein concentration in
the supernatant was determined using the Bio-Rad DC pro-
tein assay. Lysates were separated on single percentage
SDS/PAGE gels, then electrophoretically transferred to
poly(vinylidene diﬂuoride), using standard procedures. Blots
were incubated in 5% non-fat dried milk in TBST (0.02 M
Tris, pH 7.6/0.35 M NaCl/0.1% Tween-20) for 1 h at room
temperature before probing with primary antibodies against
p53 (CM-5, Novacastra) and -actin (Sigma). Secondary anti-
bodies used include peroxidase-conjugated goat anti-mouse
IgG and anti-rabbit IgG (Pierce). Probed blots were incubated
with Pierce Supersignal West Pico chemiluminescent sub-
strate and exposed to X-ray ﬁlms.
Flow cytometry
Log phase cells were irradiated at RT with a 60 Co g-
irradiator at doses of 6 or 12 Gy and incubated for 24 h.
Cells were then pulse-labeled for 1 h with BrdU (10 mM),
ﬁxed in 70% ethanol, double-stained with FITC anti-BrdU
and propidium iodide, then sorted by using a Becton Dickin-
son FACScan machine. Data were analyzed using Becton
Dickinson Cellquest Pro.
RESULTS AND DISCUSSION
The rationale for RMCE-ASAP is detailed in Figure 1. The
ﬁrst step requires generating a ﬂoxed allele in ES cells that
will serve as the substrate for subsequent exchanges
(RMCE-ready ES cell, Figure 1). The targeting strategy is
detailed in Figure 2. The frequency of targeting was 4%
(12/300 puromycin-resistant clones, analyzed by Southern
blot and long-range PCR, Figure 2).
We next tested the efﬁciency of RMCE in ES cells, using a
replacement construct encoding p53 fused to GFP (p53
GFP)t o
enable tracking p53 in individual live cells. Importantly how-
ever, GFP ﬂuorescence was not used to screen cells with
targeted events, as we wanted to develop a general method
to isolate marker-free recombinants. The exchange strategy
is detailed in Figure 3A. We picked 65 ES cell clones
resistant to 1-(-2-deoxy-2-ﬂuoro-1-b-D-arabino-furanosyl)-5-
iodouracil (FIAU) due to TK loss and analyzed their DNA
by PCR and Southern blot. Strikingly, 54 proper recombi-
nants were identiﬁed, indicating very high RMCE efﬁciency
(83%). RMCE also proved to be precise, as no aberrant
bands were detected in PCR and Southern blots
(Figure 3A). p53
+/GFP ES clones were analyzed by western
blot with an antibody against p53, and found to express an
additional band at the expected size (ca. 80 kDa). Surpris-
ingly, the fusion of GFP to p53 apparently altered p53 stabil-
ity: steady-state levels of p53GFP were much higher than
those of wild-type p53 (p53
WT) in unstressed cells, and did
not vary signiﬁcantly after DNA damage, so that the levels
for both p53
WT and p53
GFP were similar after adriamycin
treatment (Figure 3A).
Six independent p53
+/GFP clones were injected into blasto-
cysts and transferred to pseudo-pregnant females using stan-
dard procedures. Strikingly, no pregnancies were obtained. It
has been shown that the p53 pathway is regulated very differ-
ently in ES and somatic cells: ES cells contain relatively high
p53 levels and lack the p53-mediated DNA damage responses
found in somatic cells (18). This, together with the observa-
tion that p53 levels decrease during mouse embryogenesis
(19), suggested an explanation for the observed lack of
pregnancies: we speculate that the high levels of p53
GFP in
the ES cells injected into blastocysts might have prevented
normal embryonic development once these cells began to dif-
ferentiate and the p53 pathway became functional.
To test this possibility, we performed RMCE with a p53
fusion gene in which the p53 proline-rich domain (PRD)
Figure 2. Generating ES cells with a p53 RMCE-ready locus. The p53 gene is
contained in a 17 kb-long EcoRI (RI) fragment (black boxes: coding
sequences, white boxes: UTRs). The Flox targeting construct (below), the
sequence which was verified before use (Materials and Methods), contains (i)
a 3.4 kb-long 50 homology region; (ii) 0.2 kb upstream of coding sequences,
an EcoRI site and L3, a mutant loxP [loxP257, (14)]; (iii) p53 exons; (iv) 0.4
kb downstream, a puroDTK fusion gene (puDTK) for positive/negative
selection (21) and an inverted WT loxP (1L); (v) a 1.2 kb-long 30 homology
region and (vi) the diphteria a-toxin (DTA) gene for targeting enrichment.
The recombinants resulting from the depicted crossing-overs are identified by
a 6.5 kb band in Southern blot with probe A and a 3 kb band by PCR with
primers a and b. A representative Southern, and PCR of one positive (b) and
two negative clones, are shown.
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DP), and the p53
DP was fused to GFP. We
used this mutant because deleting the proline-rich domain
decreases stability and compromises DNA-damage responses
in vivo (5). According to our hypothesis, this hypomorphic
mutant should not prevent embryonic development. RMCE
with a p53
DPGFP replacement plasmid was again very efﬁcient
and western blots revealed an additional band of the predicted
molecular weight only in p53
+/DPGFP ES cells (Figure 3B). As
expected, the PRD deletion correlated with lower expression
levels: p53
DPGFP was much less abundant than p53WT in all
p53+/DPGFP clones (Figure 3B). We next determined whether
p53
+/DPGFP ES cells could generate chimeric mice and trans-
mit the modiﬁed allele through the germline. Two p53
+/DPGFP
ES cell clones were injected into blastocysts and highly
chimeric (>80%) mice were obtained. Heterozygote pups
were recovered from the mating the chimeras with WT
mice (Figure 3C). These data demonstrate that marker-free
RMCE is very efﬁcient in ES cells and allows germline trans-
mission of a targeted mutation (see Figure 1, path A).
We next determined whether the RMCE approach
could be used to target mutations at the p53 allele in
somatic cells (Figure 1, path B). We ﬁrst veriﬁed that the
Figure 3. Performing RMCE in ES cells. (A) RMCE with a p53
GFP plasmid. The exchange plasmid, the sequence which was verified before use, contains p53
GFP
coding sequences flanked by L3 and 1L sites. It was electroporated with a Cre expression plasmid. FIAU-resistant clones were analyzed by PCR with primers b
and c and Southern blot with probe B. Both approaches led to identical results and identified 54/65 RMCE recombinants. Representative clones (P–Z) are shown
(left), analyzed by PCR (top) and Southern (bottom): all clones but Q and T are positive with both assays. All positive clones produced a band of the expected
size by PCR, indicating correct recombination at 1L, and displayed only the expected 12 and 5 kb bands by Southern, indicating correct recombination at L3. The
absence of bands of aberrant size in Southerns also indicated that the exchange plasmid was neither rearranged nor inserted at ectopic sites. Thus RMCE was
efficient and accurate. Recombinant clones were analyzed by western blot with an antibody to p53. In the representative western (right), cells from two
independent p53
+/GFP ES clones were left untreated or treated with adriamycin (ADR) at 0.5 mg/ml for 24 h, and protein extracts were prepared. p53
GFP migrated
at the expected size of 80 kDa and was expressed at unexpectedly high levels regardless of stress. (B) RMCE with a p53
DPGFP plasmid. The p53
DPGFP exchange
construct (which sequence was verified before use) differed from the p53
GFP construct only in that it contains a mutated exon 4 (4*) encoding a PRD deletion.
RMCE was again very efficient, with 10/12 FIAU-resistant clones producing a 3 kb band by PCR with primers b and c. A western analysis of four FIAU-resistant
clones is shown below (with low/high exposures: Lo X/Hi X). As expected, all except clone x expressed p53
DPGFP. p53
DPGFP migrated at the expected size of 75
kDa and accumulated after stress, but at lower levels than p53
WT. (C) Germline transmission of the p53
DPGFP mutation. DNA of seven littermates (U42–U48),
obtained from mating a p53
DPGFP chimera with a WT mouse, was analyzed by PCR with primers d and e (see B), with DNA from WT, p53
+/DP and p53
DP/DP
MEFs (5) as controls. U45, a p53
+/DPGFP mouse, demonstrated transmission of the mutation.
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RMCE) could be transmitted
through the germline by mating p53
RMCE/+ chimeras with
p53
+/  mice (20) (Figure 4). Importantly, this allowed us to
generate p53
RMCE/  MEFs, which were used to test RMCE
at the p53 locus in somatic cells. We ﬁrst attempted RMCE
in MEFs by electroporating p53
RMCE/  MEFs with a Cre-
expression plasmid and the p53
GFP plasmid, followed by
selection with FIAU or ganciclovir. Strikingly, no clones
with an exchanged allele were identiﬁed (data not shown).
RMCE with p53
GFP in ES cells showed that p53
GFP is
expressed at high levels (Figure 3A), and as mentioned
before, the p53 pathway that can be activated in MEFs is
not readily activated in ES cells (18). The results above
suggest that high levels of p53
GFP could be tolerated by ES
cells but toxic to MEFs, so that MEFs in which an RMCE
had occurred failed to proliferate. To test this possib-
ility, p53
RMCE/  MEFs were electroporated with the p53
GFP
replacement construct with or without a Cre-expression
plasmid, then analyzed by ﬂuorescence microscopy 48 h
after electroporation. The experiment was done without selec-
tion to enable observation of cells under conditions where a
failure to proliferate would not derive from FIAU or ganci-
clovir toxicity but rather solely from the effects of p53
GFP.
We observed a few ﬂuorescent cells only when the Cre
expression plasmid was co-electroporated, suggesting that
such cells resulted from RMCE. Importantly, the rare ﬂuores-
cent cells had a ﬂat, ‘fried-egg’ appearance typical of senes-
cent cells (Figure 5A), and when plates were observed 5 days
later, the cells had detached. Altogether, the results suggest
Figure 4. Germline transmission of the p53 RMCE-ready locus. p53
RMCE/+
ES cells were injected into blastocysts to generate chimeric mice. Chimeras
(>80%) were then mated with p53
+/  mice (Taconic) and MEFs were
prepared. MEFs were first genotyped by PCR with primers a and b (see
Figure 2) to detect the PuroDTK marker of the RMCE allele (top). This
revealed germline transmission of the p53 RMCE-ready locus in MEFs 1, 2
and 6. Each of these three MEF clones was further analyzed (bottom) with
primers f and g (left lanes) and h and i (right lanes), routinely used to
genotype p53
+/  mice (sequences in Materials and Methods). Primers f and g
amplify a 320 bp product from a WT or RMCE allele, while primers h and i
specifically amplify a 150 bp product from the Neo marker in the KO allele.
MEF 1 are p53RMCE/+ and MEFs 2 and 6 are p53
RMCE/  cells.
Figure 5. Performing RMCE in MEFs. (A) RMCE with the p53
GFP plasmid leads to the transient observation of cells with intense nuclear fluorescence.
p53
RMCE/  MEFs, electroporated with a Cre expression plasmid and the p53
GFP exchange plasmid, were analyzed 48 h later by fluorescence microscopy.
A typical field (left to right: fluorescence, phase contrast, merged) with a fluorescent cell (arrow) is shown. The fluorescent cell is enlarged (extreme
right). (B) RMCE with the p53
DPGFP plasmid. p53
RMCE/  MEFs, electroporated with a Cre expression plasmid and the p53
DPGFP plasmid, were selected with
ganciclovir. PCR with primers d and e (Figure 3B) indicated that 9/22 ganciclovir-resistant clones integrated the DP mutation [top row, a representative analysis
of 10 clones (Q–Z) is shown]. PCR with primers b and c next verified that the detected PRD deletions resulted from RMCE at the p53 locus, not random
integration (middle row, as expected clones R, S, T and W are positive, but not Q). Western analysis of positive clones (bottom row) showed that p53
DPGFP
accumulated after ADR, but at lower levels than p53
WT. (C) Phenotypic assay of p53
DPGFP: loss of cell cycle control. Asynchronous p53
RMCE/  and p53
DPGFP/ 
MEFs left untreated, or irradiated with doses of 6 or 12 Gy, were analyzed (top shows a typical experiment; bottom plots results from >4 independent
experiments and >3 independent MEFs). Note that the p53
RMCE locus encodes a WT p53.
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GFP-expressing MEFs, but
they die rapidly owing to p53GFP toxicity.
We also performed RMCE in p53
RMCE/  MEFs with the
p53
DPGFP construct. p53
DPGFP-expressing MEFs were viable,
recovered with an efﬁciency of  40%, and, as expected from
ES cell experiments, expressed a p53
DPGFP protein at much
lower levels than p53WT (Figure 5B). Unlike WT MEFs,
p53
DP/DP MEFs are unable to arrest cycling after irradia-
tion (5). Likewise, we found that irradiation doses that
arrested p53
RMCE/  MEFs (which express a wild-type p53
from the RMCE-ready locus, see Figure 2) did not arrest
p53
DPGFP/  MEFs (Figure 5C). These data show that a single
RMCE-ASAP reaction in heterozygous MEFs enables
detection of a recessive phenotype. The results conﬁrm that
deleting the proline rich domain leads to less active p53
with impaired cell cycle control, and also indicate that a
GFP C-terminal fusion can dramatically alter p53 regulation.
A summary of our results is presented in Table 1.
These data report the development and implementation of
an improved RMCE approach that enables efﬁcient allele
modiﬁcation in ES cells to generate mice and in heterozygous
MEFs to accelerate phenotypic analyses. The success of
RMCE-ASAP relied on the integrated use of inverted
heterologous loxP sites, a positive/negative selection marker
that preserves the germline capacity of ES cells, and, for
somatic cells, the existence of a knock-out allele of the
gene of interest. These characteristics should make RMCE-
ASAP a robust and general technology for analysis of mam-
malian genes under conditions that preserve normal control
mechanisms in different tissues. In addition, RMCE-ASAP
could be used to generate ﬁbroblastic cell lines tailored for
the repeated targeting of widely studied genes (p53, c-myc,
NF-KB, etc.).
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